Angelman Syndrome Foundation's News Room is an aggregation of several sources. We will post exciting announcements pertaining to ASF in addition to news about Angelman syndrome from within our community and from external media sources. See a story you think we should share? Send an email to firstname.lastname@example.org with the information. Thank you!
Ovid is working with patients and families to develop failed drugs for rare and Orphan brain diseases, starting with Angelman syndrome . . .
Ovid Therapeutics and Lundbeck A/S pharmaceuticals have entered into a worldwide licensing agreement for Gaboxadol, a drug that Ovid plans to use in separate upcoming clinical trials to treat Angelman syndrome and Fragile X syndrome.
The 2015 ASF Research Grants will conduct clinical and pre-clinical research aimed at finding therapeutics, establishing biomarkers for future clinical trials, and improving symptoms of AS.These studies feature unique, innovative approaches to resolving AS symptoms and understanding the genetic complexities of AS. The AS research community continues to grow and move us in the direction of ultimately finding a cure for AS!
Approximately 30 million individuals in the United States are affected by a rare disorder or disease. On the last day of February every year, hundreds of patient organizations from more than 80 countries and regions worldwide conduct awareness-raising activities to celebrate Rare Disease Day.
The Angelman Syndrome Foundation (ASF) joins the international Angelman syndrome community in celebrating International Angelman Day on Sunday, Feb. 15 as ASF-funded research continues to make headway in identifying potential treatments for Angelman syndrome.